Other genes carry a differential risk depending on the BC immunophenotype: BARD1, RAD51C, and RAD51D mutations are associated with a higher risk of ER-negative BCs, including TNBCs, whereas ATM and CHK2 mutations are associated with a higher risk of ER+ BC. The gene discussed is RAD51D; the disease is breast cancer.